HOME >> BIOLOGY >> NEWS
Drug lowers inflammatory markers associated with risk for heart attack

The trial included MI patients who carry at-risk variants in the FLAP gene or in the leukotriene A4 hydrolase gene. Of 268 patients screened, 191 were carriers of at-risk variants in FLAP (87 percent) or leukotriene A4 hydrolase (13 percent). Individuals were enrolled in April 2004 and were followed up by designated cardiologists from the Landspitali University Hospital in Iceland until September 2004. Patients were first randomized to receive 250 mg/d of DG-031, 500 mg/d of DG-031, 750 mg/d of DG-031, or placebo. After a 2-week washout period, patients received DG-031 if they had received placebo first or placebo if they had received DG-031 first. Treatment periods lasted for 4 weeks.

The researchers found that levels of several biomarkers linked to arterial inflammation and risk of MI decreased. In response to 750 mg/d of DG-031, production of leukotriene B4 was significantly reduced by 26 percent and myeloperoxidase was significantly reduced by 12 percent. The higher 2 doses of DG-031 produced a nonsignificant reduction in C-reactive protein (16 percent) at 2 weeks. However, there was a more pronounced reduction (25 percent) in C-reactive protein at the end of the washout period that was significant and persisted for another 4 weeks thereafter. An 8-day, open-label follow-up study with 75 patients with the same genetic and disease profile as in the Phase IIa was conducted to further examine the effect of DG031 on CRP and myeloperoxidase. The results of this study showed that the 750mg/d dose of DG031, when administered as 250 mg 3 times daily resulted in a 38 percent reduction in CRP levels, as well as a 31 percent reduction in myeloperoxidase levels measured 6 hours after dosing on day 8. In both studies, the FLAP inhibitor DG-031 was well-tolerated and was not associated with any serious adverse events.

"When taken together, the data from our MI gene-isolation study and the clinical trial reported herein show that DG-031 is a safe and w
'"/>

Contact: Edward Farmer
edward.farmer@decode.is
354-570-2819
JAMA and Archives Journals
10-May-2005


Page: 1 2 3 4

Related biology news :

1. Columbine flowers develop long nectar spurs in response to pollinators
2. Nondanger signal lowers immune reactions
3. Plants with male and bisexual flowers on the same plant are better mothers
4. Flowers shape themselves to guide their pollinators to the pollen
5. Orange juice beverage fortified with plant sterols lowers indicators of heart disease risk
6. How did bilaterally symmetric flowers evolve from radially symmetric ones?
7. Genetic snooze button governs timing of spring flowers
8. Wild bees and the flowers they pollinate are disappearing together
9. Low-to-moderate prenatal alcohol exposure lowers IQ at age 10
10. How flowers changed the world a new book by Field Museum scientist
11. Lots of flowers and trees, not enough birds and bees

Post Your Comments:
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has announced ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo ... In its first six months of existence, the Lab has ... support for local law enforcement. "Because our number ...
(Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
(Date:11/5/2014)... Santamaria, associate professor of biology in the UTSA ... in the nation selected to receive a two-year ... for Exploratory Research (EAGER). The funding supports President ... researchers to create new technology that will demystify ... complex behaviors in neuroscience are broken into the ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/21/2014)... GUELPH, ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... month and nine month periods ended September 30, 2014.  Biorem,s complete ... SEDAR ( www.sedar.com ). Financial Summary:Three-months ended ... CDN$,000 except per share data) , 2014 , ... , 2,282 , 5,281 , 6,715 ...
(Date:11/18/2014)... (PRWEB) November 17, 2014 ... open architecture blade-based and rackmount computing infrastructure, today ... K80 dual-GPU accelerator throughout its GPU-enabled blade server ... of the company’s latest proprietary 80-lane Gen3 PCIe ... discrete NVIDIA Tesla K80 dual-GPU accelerator cards in ...
(Date:11/18/2014)... New Brunswick, NJ (PRWEB) November 18, 2014 ... of Data Quality and Transparency Reporting solutions, announced ... has gone live using its Consummate Provider™ solution ... Consummate Provider™ is a Global, SaaS based, Data ... Science organizations and their third party Providers improve ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
Cached News: